Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
- Author:
Bo CAI
1
;
Chun-Ji GAO
;
Hong-Hua LI
;
Jian BO
;
Wen-Rong HUANG
;
Li GAO
;
Jing-Fen SUN
;
Yi DING
;
Li-Li WANG
;
Li YU
Author Information
1. Center of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Benzamides;
Combined Modality Therapy;
Hematopoietic Stem Cell Transplantation;
Humans;
Imatinib Mesylate;
Male;
Piperazines;
therapeutic use;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
therapy;
Pyrimidines;
therapeutic use;
Transplantation, Homologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2010;18(1):173-176
- CountryChina
- Language:Chinese
-
Abstract:
The study was purposed to explore the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) combined with Imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph(+)ALL) patients. From 2007 to 2008, 3 patients with Ph(+)ALL were treated with allogeneic hematopoietic stem cell transplantation and Imatinib, and the follow-up ended at Oct 21(st) 2009. 1 patient received HSCT from matched sibling donor and 2 patients from haploidentical related donors. All 3 patients achieved complete remission before transplantation and were treated with Imatinib for distinct time at different periods before and/or after transplantation. The level of bcr/abl mRNA was monitored using real-time PCR. The results showed that all 3 patients achieved stable engraftments without severe transplantation related complications. The level of bcr/abl mRNA declined and achieved zero level finally. In conclusion, the allo-HSCT combined with Imatinib is an effective therapy regimen for Ph(+)ALL patients.
